New drugs for breast cancer

British Medical Bulletin

Volumn 96, Issue 1, 2010, Pages 111-129

  Tookman, Laura ^a   Roylance, Rebecca ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

angiogenesis; breast cancer; HER2; PARP inhibitors; targeted therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; LAPATINIB; LETROZOLE; NAVELBINE; NERATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; TRASTUZUMAB DM1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB;

ACNEIFORM RASH; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOGENESIS; AREA UNDER THE CURVE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CARDIOTOXICITY; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; DIARRHEA; DIMERIZATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOGENE NEU; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; RECURRENT CANCER; REGULATORY MECHANISM; REVIEW; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DESIGN; ENZYME INHIBITORS; FEMALE; HUMANS; POLY ADENOSINE DIPHOSPHATE RIBOSE; RECEPTOR, ERBB-2;

EID: 78649671555     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldq029     Document Type: Review

References (60)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Yarden Y. The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl. 4):S3-S8.
3. Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
5. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-84.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
7. Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 2004;59:1-12.
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuVant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
9. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuVant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
10. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuVant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
11. Slamon D, Elermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC ! T) with doxorubicin and cyclophospha-mide followed by docetaxel and trastuzumab (AC ! TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2009; abstract 62.
12. Slamon D, Suman VJ, Davidson NE et al. Phase III randomised trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC ! T) with doxorubicin and cyclophospha-mide followed by docetaxel and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;(Suppl. 1):S5.
13. Perez EA, Suman VJ, Davidson NE et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuVant breast cancer trial. San Antonio Breast Cancer Symposium 2009; abstract 80.
14. Spielmann M, Roche H, Delozier T et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 Trial. J Clin Oncol 2009;27:6129-34.
15. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-51.
16. Lee S, Yang W, Lan KH et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 2002;62:5703-10.
17. Real PJ, Benito A, Cuevas J et al. Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L. Cancer Res 2005;65:8151-7.
18. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. AdjuVant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
19. Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuVant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009;27:5685-92.
20. Scaltriti M, Rojo F, Ocana A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38.
21. Ritter CA, Perez-Torres M, Rinehart C et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007;13:4909-19.
22. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastu-zumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.
23. Clark AS, West K, Streicher S et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707-17.
24. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive adVanced breast cancer. N Engl J Med 2006;355:2733-43.
25. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008;83:679-86.
26. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18:2349-51.
27. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993-9.
28. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9.
29. O'Shaughnessy J, Blackwell KL, Burstein H et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2\+ metastatic breast cancer progressing on trastuzumab therapy. ASCO Meeting Abstracts 2008;26:1015.
30. Gelmon KA, Fumoleau P, Verma S et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol (Meeting Abstracts) 2008;26:1026.
31. Wong KK, Fracasso PM, Bukowski RM et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009;15:2552-8.
32. Swaby R, Blackwell K, Jiang Z et al. Neratinib in combination with trastuzumab for the treatment of adVanced breast cancer: a phase I/II study. J Clin Oncol (Meeting Abstracts) 2009;27:1004.
33. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704.
34. Vogel CL, Burris HA, Limentani S et al. A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2\+ metastatic breast cancer (MBC): final results. J Clin Oncol (Meeting Abstracts) 2009;27:1017.
35. Lu CH, Wyszomierski SL, Tseng LM et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007;13:5883-8.
36. Andre F, Campone M, Hurvitz SA et al. Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol (Meeting Abstracts) 2008;26:1003.
37. Jerusalem GH, Dieras V, Cardoso F et al. Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol (Meeting Abstracts) 2008;26:1057.
38. De Graffenried LA, Friedrichs WE, Russell DH, et al., Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004, 10; 8059-67.
39. Chan S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally adVanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22.
40. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
41. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-9.
42. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
43. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
44. Linderholm BK, Lindh B, Beckman L et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer 2003;4:340-7.
45. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
46. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
47. Miles D, Chan A, Romieu G et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol (Meeting Abstracts) 2008;26:LBA1011.
48. Pivot X, Verma S, Thomssen C et al. Clinical benefit of bevacizumab (BV) plus first-line doc-etaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study. J Clin Oncol (Meeting Abstracts) 2009;27:1094.
49. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol (meeting abstracts) 2009;27:1005.
50. Finkenzeller G, Weindel K, Zimmermann W et al. Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1. Angiogenesis 2004;7:59-68.
51. Scheuer W, Friess T, Hasmann M. Enhanced antitumour effect by combination of HER2-targeting antibodies with bevacizumab in a human breast cancer xenograft model. Eur J Cancer Suppl 2006;4:66.
52. Pegram M, Chan D, Dickmann R et al. Phase II combined biological therapy targeting the HER2 protooncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 2006;100(Suppl. 1): [abstract 301]. S28.
53. Rugo HS, Franco S, Munster P et al. A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2\+ metastatic breast cancer (MBC). J Clin Oncol (meeting abstracts) 2008;26:1042.
54. Barrios C, Liu M-C, Lee SC et al. Phase III randomized trial of sunitinib (SU) vs. capecitabine (C) in patients (Pts) with previously treated HER2-negative adVanced breast cancer (ABC). San Antonio Breast Cancer Symposium 2009; abstract 46.
55. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
56. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002;8:571-6.
57. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
58. Tutt AN, Lord CJ, McCabe N et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005;70:139-48.
59. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
60. O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol (meeting abstracts) 2009;27:3.